What is the equity of Innoviva this year?
Innoviva has equity of 674.96 M USD this year.
Innoviva Equity 2024
Innoviva Equity
674.96 M USD
Ticker
INVA
ISIN
US45781M1018
WKN
A2AC9U
In 2024, Innoviva's equity was 674.96 M USD, a 19.29% increase from the 565.8 M USD equity in the previous year.
Innoviva Aktienanalyse
What does Innoviva do?
Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Innoviva's Equity
Innoviva's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Innoviva's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Innoviva's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Innoviva's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Innoviva’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Innoviva stock
What was the equity of Innoviva compared to the previous year?
The equity of Innoviva has increased/decreased by 19.29% increased compared to the previous year.
What impact does a high equity have on investors of Innoviva?
A high equity is advantageous for investors of Innoviva as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Innoviva?
A low equity can be a risk for investors of Innoviva, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Innoviva affect the company?
An increase in equity of Innoviva can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Innoviva affect the company?
A reduction in equity of Innoviva can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Innoviva?
Some factors that can affect the equity of Innoviva include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Innoviva so important for investors?
The equity of Innoviva is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Innoviva take to change the equity?
To change equity, Innoviva can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Innoviva pay?
Over the past 12 months, Innoviva paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 3.89 %. For the coming 12 months, Innoviva is expected to pay a dividend of 0 USD.
What is the dividend yield of Innoviva?
The current dividend yield of Innoviva is 3.89 %.
When does Innoviva pay dividends?
Innoviva pays a quarterly dividend. This is distributed in the months of December, April, July, October.
How secure is the dividend of Innoviva?
Innoviva paid dividends every year for the past 0 years.
What is the dividend of Innoviva?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Innoviva located?
Innoviva is assigned to the 'Health' sector.
Wann musste ich die Aktien von Innoviva kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Innoviva from 9/30/2015 amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2015.
When did Innoviva pay the last dividend?
The last dividend was paid out on 9/30/2015.
What was the dividend of Innoviva in the year 2023?
In the year 2023, Innoviva distributed 0 USD as dividends.
In which currency does Innoviva pay out the dividend?
The dividends of Innoviva are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Innoviva stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Innoviva
Our stock analysis for Innoviva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innoviva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
